Antibiotics clinical development and pipeline

Current Topics in Microbiology and Immunology

Volumn 398, Issue , 2016, Pages 447-474

  Hesterkamp, Thomas ^a  

^a HELMHOLTZ CENTRE FOR INFECTION RESEARCH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

14 O [(3 HYDROXYMETHYLPHENYLTHIO)ACETYL]MUTILIN; ANTIBIOTIC AGENT; AVIBACTAM PLUS CEFTAZIDIME; BRILACIDIN; CEFTOLOZANE PLUS TAZOBACTAM; DALBAVANCIN; DEBIO 1452; DELAFLOXACIN; ERAVACYCLINE; FINAFLOXACIN; FUSIDIC ACID; GEPOTIDACIN; LEFAMULIN; MRX 1; MUREPAVADIN; NEMONOXACIN; OMADACYCLINE; ORITAVANCIN; OZENOXACIN; PEXIGANAN; PLAZOMICIN; RADEZOLID; RELEBACTAM; SOLITHROMYCIN; SUVRATOXUMAB; TD 1792; TEDIZOLID; TELAVANCIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZABOFLOXACIN; ANTIINFECTIVE AGENT;

ABDOMINAL INFECTION; ACINETOBACTER BAUMANNII; ANTIBACTERIAL ACTIVITY; ARTICLE; BACTERIAL SKIN DISEASE; BACTERIAL STRAIN; BLOODSTREAM INFECTION; CARBAPENEM RESISTANT ENTEROBACTERIACEAE; COMMUNITY ACQUIRED PNEUMONIA; DRUG APPROVAL; DRUG EFFICACY; DRUG INDICATION; DRUG RESEARCH; DRUG SENSITIVITY; HOSPITAL ACQUIRED PNEUMONIA; HUMAN; KLEBSIELLA PNEUMONIAE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MORBIDITY; MORTALITY; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; PYELONEPHRITIS; TREATMENT RESPONSE; URINARY TRACT INFECTION; VENTILATOR ASSOCIATED PNEUMONIA; BACTERIAL INFECTIONS; BACTERIUM; CHEMISTRY; DRUG EFFECTS; GENETICS; METABOLISM; MICROBIOLOGY; MULTIDRUG RESISTANCE;

ANTI-BACTERIAL AGENTS; BACTERIA; BACTERIAL INFECTIONS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; HUMANS;

EID: 85007386159     PISSN: 0070217X     EISSN: 21969965     Source Type: Book Series    
DOI: 10.1007/82_2015_451     Document Type: Article

References (38)

1. Ambrose PG, Bhavnani SM, Rubino CM, Louie A, Gumbo T, Forrest A, Drusano GL (2007) Pharmacokinetics-pharmacodynamics of antimicrobial therapy: it’s not just for mice anymore. Clin Infect Dis 44:79-86.
2. Ambrose PG, Bhavnani SM, Dudley MN, Ellis-Grosse E, Rubino CM, Drusano GL (2012) New EMA guideline for antimicrobial development. Lancet Infect Dis 412:265-266.
3. Andes D, Craig WA (2002) Animal models of pharmacokinetics and pharmacodynamics: a critical review. Int J Antimicrob Agents 19:261-268.
4. Bagdasarian N, Rao K, Malani PN (2015) Diagnosis and treatment of Clostridium difficile in adults: a systematic review. JAMA 313:398-408.
5. Bassetti M, Righi E (2013) Multidrug-resistant bacteria: what is the threat? Hematol Am Soc Hematol Educ Prog 2013:428-432.
6. Bassetti M, Merelli M, Temperoni C, Astilean A (2013) New antibiotics for bad bugs: where are we? Ann Clin Microbiol Antimicrob 12:22.
7. Bax R, Green S (2015) Antibiotics: the changing regulatory and pharmaceutical industry paradigm. J Antimicrob Chemother 70:1281-1284.
8. Boucher HW, Talbot GH, Bradley JS, Edwards JE, Gilbert D, Rice LB, Scheld M, Spellberg B, Bartlett J (2009) Bad bugs, no drugs: no ESKAPE! an update from the Infectious Diseases Society of America. Clin Infect Dis 48:1-12.
9. Boucher HW, Talbot GH, Benjamin DK Jr., Bradley J, Guidos RJ, Jones RN, Murray BE, Bonomo RA, Gilbert D (2013) Infectious Diseases Society of America. 10 × ‘20 progress development of new drugs active against gram-negative bacilli: an update from the Infectious Diseases Society of America. Clin Infect Dis 56:1685-1694.
10. Bush K (2013) Proliferation and significance of clinically relevant β-lactamases. Ann N Y Acad Sci 1277:84-90.
11. Calfee DP (2012) Crisis in hospital-acquired, healthcare-associated infections. Annu Rev Med 3:359-371.
12. Crandon JL, Nicolau DP (2013) Human simulated studies of aztreonam and aztreonam-avibactam to evaluate activity against challenging gram-negative organisms, including metallo-β-lactamase producers. Antimicrob Agents Chemother 57:3299-3306.
13. Drawz SM, Papp-Wallace KM, Bonomo RA (2014) New β-lactamase inhibitors: a therapeutic renaissance in an MDR world. Antimicrob Agents Chemother 58:1835-1846.
14. Garnacho-Montero J, Escoresca-Ortega A, Fernández-Delgado E (2015) Antibiotic de-escalation in the ICU: how is it best done? Curr Opin Infect Dis 28:193-198.
15. Hawkey PM (2015) Multidrug-resistant gram-negative bacteria: a product of globalization. J Hosp Infect 89:241-247.
16. Higgins PG, Stefanik D, Page MG, Hackel M, Seifert H (2012) In vitro activity of the siderophore monosulfactam BAL30072 against meropenem-non-susceptible Acinetobacter baumannii. J Antimicrob Chemother 67:1167-1169.
17. Huang SS, Septimus E, Avery TR, Lee GM, Hickok J, Weinstein RA, Moody J, Hayden MK, Perlin JB, Platt R, Ray GT (2014) Cost savings of universal decolonization to prevent intensive care unit infection: implications of the REDUCE MRSA trial. Infect Control Hosp Epidemiol 35(Suppl 3):S23-S31.
18. Infectious Diseases Society of America (2012) White paper: recommendations on the conduct of superiority and organism-specific clinical trials of antibacterial agents for the treatment of infections caused by drug-resistant bacterial pathogens. Clin Infect Dis 55:1031-1046.
19. Karaiskos I, Giamarellou H (2014) Multidrug-resistant and extensively drug-resistant gram-negative pathogens: current and emerging therapeutic approaches. Expert Opin Pharmacother 15:1351-1370.
20. Keener AB (2014) First QIDP drug approved, but designation may fail urgent needs. Nat Med 20:690-691.
21. Koningstein M, van der Bij AK, de Kraker ME, Monen JC, Muilwijk J, de Greeff SC, Geerlings SE, van Hall MA (2014) ISIS-AR Study Group. Recommendations for the empirical treatment of complicated urinary tract infections using surveillance data on antimicrobial resistance in the Netherlands. PLoS ONE 9:e86634.
22. Kumar Kakkar A, Dahiya N (2014) The evolving drug development landscape: from blockbusters to niche busters in the orphan drug space. Drug Dev Res 75:231-234.
23. MacVane SH, Crandon JL, Nichols WW, Nicolau DP (2014) In vivo efficacy of humanized exposures of Ceftazidime-Avibactam in comparison with Ceftazidime against contemporary Enterobacteriaceae isolates. Antimicrob Agents Chemother 58:6913-6919.
24. McKellar MR, Fendrick AM (2014) Innovation of novel antibiotics: an economic perspective. Clin Infect Dis 59(Suppl 3):S104-S107.
25. Nambiar S, Laessig K, Toerner J, Farley J, Cox E (2014) Antibacterial drug development: challenges, recent developments, and future considerations. Clin Pharmacol Ther 96:147-149.
26. Nimmo GR (2012) USA300 abroad: global spread of a virulent strain of community-associated methicillin-resistant Staphylococcus aureus. Clin Microbiol Infect 18:725-734.
27. Page MG, Bush K (2014) Discovery and development of new antibacterial agents targeting Gram-negative bacteria in the era of pandrug resistance: is the future promising? Curr Opin Pharmacol 18:91-97.
28. Pucci MJ, Bush K (2013) Investigational antimicrobial agents of 2013. Clin Microbiol Rev 26:792-821.
29. Rex JH, Eisenstein BI, Alder J, Goldberger M, Meyer R, Dane A, Friedland I, Knirsch C, Sanhai WR, Tomayko J, Lancaster C, Jackson J (2013) A comprehensive regulatory framework to address the unmet need for new antibacterial treatments. Lancet Infect Dis 13:269-275.
30. Rice LB (2008) Federal funding for the study of antimicrobial resistance in nosocomial pathogens: no ESKAPE. J Infect Dis 197:1079-1081.
31. Spellberg B (2011) The antibiotic crisis: can we reverse 65 years of failed stewardship? Arch Intern Med 171:1080-1081.
32. Spellberg B (2014) The future of antibiotics. Crit Care 18:228.
33. Spellberg B, Shlaes D (2014) Prioritized current unmet needs for antibacterial therapies. Clin Pharmacol Ther 96:151-153.
34. Spellberg B, Sharma P, Rex JH (2012) The critical impact of time discounting on economic incentives to overcome the antibiotic market failure. Nat Rev Drug Discov 11:168.
35. Srinivas N, Jetter P, Ueberbacher BJ, Werneburg M, Zerbe K, Steinmann J, Van der Meijden B, Bernardini F, Lederer A, Dias RL, Misson PE, Henze H, Zumbrunn J, Gombert FO, Obrecht D, Hunziker P, Schauer S, Ziegler U, Käch A, Eberl L, Riedel K, DeMarco SJ, Robinson JA (2010) Peptidomimetic antibiotics target outer-membrane biogenesis in Pseudomonas aeruginosa. Science 327:1010-1013.
36. Tacconelli E, Cataldo MA, Dancer SJ, De Angelis G, Falcone M, Frank U, Kahlmeter G, Pan A, Petrosillo N, Rodríguez-Baño J, Singh N, Venditti M, Yokoe DS, Cookson B (2014) European Society of Clinical Microbiology. ESCMID guidelines for the management of the infection control measures to reduce transmission of multidrug-resistant Gram-negative bacteria in hospitalized patients. Clin Microbiol Infect 20, Suppl 1:1-55.
37. Tomayko JF, Rex JH, Tenero DM, Goldberger M, Eisenstein BI (2014) The challenge of antimicrobial resistance: new regulatory tools to support product development. Clin Pharmacol Ther 96:166-168.
38. Unemo M, Shafer WM (2014) Antimicrobial resistance in Neisseria gonorrhoeae in the 21st century: past, evolution, and future. Clin Microbiol Rev 27:587-613.